Sarah Cannon Cancer Network shared on LinkedIn:
“We’re proud to share that Navneet Majhail physician-in-chief of blood cancers for the Sarah Cannon Cancer Network, has been appointed president of the board of directors for the Foundation for the Accreditation of Cellular Therapy (FACT).
A recognized leader in transplantation and cellular therapy, Dr. Majhail oversees the Sarah Cannon Transplant and Cellular Therapy Network — 13 programs across the U.S. and U.K. — caring for more than 1,700 transplant and cell and gene therapy patients each year.
In this role, Dr. Majhail will help guide standards and accreditation efforts that support quality and safety as cell and gene therapy continues to advance — helping bring innovative treatments closer to patients’ homes.
In addition to his new role, Dr. Majhail also recently was awarded a Lifetime Achievement Award from the ASTCT Survivorship Special Interest Group (SIG). This award recognizes outstanding, long-term contributions to the field of hematopoietic cell transplantation (HCT) survivorship. It honors SIG members for dedication to survivorship practice through research, publications, mentorship, and leadership.
Congratulations, Dr. Majhail, and thank you for representing Sarah Cannon on the national stage.”
Erika Hamilton, Chair, Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared Sarah Cannon Research Institute’s post on LinkedIn:
“So proud of Navneet Majhail’s leadership in being named president of the board for the Foundation for the Accreditation of Cellular Therapy (FACT).
We are Sarah Cannon Research Institute proud!”
More posts about Sarah Cannon Research Institute.